Antiangiogenic and anti-invasive effects of sunitinib on experimental human glioblastoma

Neuro-Oncology

Volumn 9, Issue 4, 2007, Pages 412-423

  De Boüard, Sophie ^a,e   Herlin, Paulette ^a   Christensen, James G ^b   Lemoisson, Edwige ^a   Gauduchon, Pascal ^a   Raymond, Eric ^c   Guillamo, Jean Sébastien ^a,d  

^a UNIVERSITÉ DE CAEN   (France)

^b PFIZER INC   (United States)

^c BEAUJON HOSPITAL   (France)

^d CHU CÔTE DE NACRE   (France)

^e CENTRE FRANÇOIS BACLESSE   (France)

Author keywords

Angiogenesis; Antiangiogenic therapy; Glioblastoma; Invasion; Sunitinib

Indexed keywords

FOCAL ADHESION KINASE; SUNITINIB; ANGIOGENESIS INHIBITOR; INDOLE DERIVATIVE; PROTEIN TYROSINE KINASE; PYRROLE DERIVATIVE;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BRAIN SLICE; CONTROLLED STUDY; DRUG MEGADOSE; GENETIC TRANSFECTION; GLIOBLASTOMA; HUMAN; HUMAN CELL; MICROVASCULATURE; MOUSE; NONHUMAN; PROTEIN PHOSPHORYLATION; SURVIVAL; TUMOR NECROSIS; ANIMAL; BRAIN; BRAIN TUMOR; CANCER INVASION; CANCER TRANSPLANTATION; DRUG EFFECT; DRUG SCREENING; FLOW CYTOMETRY; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; NEOVASCULARIZATION (PATHOLOGY); NUDE MOUSE; ORGAN CULTURE TECHNIQUE; PATHOLOGY; PHOSPHORYLATION; TUMOR CELL LINE; VASCULARIZATION; WESTERN BLOTTING;

ANGIOGENESIS INHIBITORS; ANIMALS; BLOTTING, WESTERN; BRAIN; BRAIN NEOPLASMS; CELL LINE, TUMOR; FLOW CYTOMETRY; FOCAL ADHESION PROTEIN-TYROSINE KINASES; GLIOBLASTOMA; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; INDOLES; MICE; MICE, NUDE; NEOPLASM INVASIVENESS; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; ORGAN CULTURE TECHNIQUES; PHOSPHORYLATION; PYRROLES; SRC-FAMILY KINASES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 38449097166     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1215/15228517-2007-024     Document Type: Article

References (45)

1. Kleihues P, Burger PC, Collins VP, Newcomb EW, Oghaki H, Cavanee WK. Glioblastoma. In: Kleihues P, Cavanee WK, eds. Tumours of the Nervous System: Pathology and Genetics. Lyon, France: International Agency for Research on Cancer Press; 2000;29-98.
2. Plate KH, Risau W. Angiogenesis in malignant gliomas. Glia. 1995; 15:339-347.
3. Bernstein JJ. Local invasion and intraparenchymal metastasis of astrocytomas. Neuropathol Appl Neurobiol. 1996;22:421-424.
4. Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature. 2005;438:967-974.
5. Puduvalli VK. Inhibition of angiogenesis as a therapeutic strategy against brain tumors. Cancer Treat Res. 2004;117:307-336.
6. Carmeliet P. Angiogenesis in life, disease and medicine. Nature. 2005;438:932-936.
7. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 1996; 86:353-364.
8. Kaur B, Tan C, Brat DJ, Post DE, Van Meir EG. Genetic and hypoxic regulation of angiogenesis in gliomas. J Neurooncol. 2004;70:229-243.
9. Ferrara N. VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer. 2002;2:795-803.
10. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003;9:669-676.
11. Plate KH, Breier G, Millauer B, Ullrich A, Risau W. Up-regulation of vascular endothelial growth factor and its cognate receptors in a rat glioma model of tumor angiogenesis. Cancer Res. 1993;53:5822-5827.
12. Samoto K, Ikezaki K, Ono M, et al. Expression of vascular endothelial growth factor and its possible relation with neovascularization in human brain tumors. Cancer Res. 1995;55:1189-1193.
13. Schmidt NO, Westphal M, Hagel C, et al. Levels of vascular endothelial growth factor, hepatocyte growth factor/scatter factor and basic fibroblast growth factor in human gliomas and their relation to angiogenesis. Int J Cancer. 1999;19:10-18.
14. Guha A, Dashner K, Black PM, Wagner JA, Stiles CD. Expression of PDGF and PDGF receptors in human astrocytoma operation specimens supports the existence of an autocrine loop. Int J Cancer. 1995;60:168-173.
15. Hermanson M, Funa K, Hartman M, et al. Platelet-derived growth factor and its receptors in human glioma tissue: expression of messenger RNA and protein suggests the presence of autocrine and paracrine loops. Cancer Res. 1992;52:3213-3219.
16. Plate KH, Breier G, Farrell CL, Risau W. Platelet-derived growth factor receptor-beta is induced during tumor development and upregulated during tumor progression in endothelial cells in human gliomas. Lab Invest. 1992;67:529-534.
17. Wang D, Huang HJ, Kazlauskas A, Cavenee WK. Induction of vascular endothelial growth factor expression in endothelial cells by platelet-derived growth factor through the activation of phosphatidylinositol 3-kinase. Cancer Res. 1999;59:1464-1472.
18. Guo P, Hu B, Gu W, et al. Platelet-derived growth factor-B enhances glioma angiogenesis by stimulating vascular endothelial growth factor expression in tumor endothelia and by promoting pericyte recruitment. Am J Pathol. 2003;162:1083-1093.
19. Lokker NA, Sullivan CM, Hollenbach SJ, Israel MA, Giese NA. Platelet-derived growth factor (PDGF) autocrine signaling regulates survival and mitogenic pathways in glioblastoma cells: evidence that the novel PDGF-C and PDGF-D ligands may play a role in the development of brain tumors. Cancer Res. 2002;62:3729-3735.
20. Westermark B, Heldin CH, Nister M. Platelet-derived growth factor in human glioma. Glia. 1995;15:257-263.
21. Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D. Benefits of targeting both pericytes and endothelial cells in the tumor vascula-ture with kinase inhibitors. J Clin Invest. 2003;111:1287-1295.
22. Erber R, Thurnher A, Katsen AD, et al. Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. FASEB J. 2004;18:338-340.
23. Laird AD, Christensen JG, Li G, et al. SU6668 inhibits Flk-1/KDR and PDGFRbeta in vivo, resulting in rapid apoptosis of tumor vasculature and tumor regression in mice. FASEB J. 2002;16:681-690.
24. Sakamoto KM. Su-11248 Sugen. Curr Opin Investig Drugs. 2004;5: 1329-1339.
25. Mendel DB, Laird AD, Xin X, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endo-thelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res. 2003;9:327-337.
26. Schueneman AJ, Himmelfarb E, Geng L, et al. SU11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor models. Cancer Res. 2003;63:4009-4016.
27. Faivre S, Delbaldo C, Vera K, et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol. 2006;24:25-35.
28. Motzer RJ, Michaelson MD, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol. 2006;24:16-24.
29. de Bouard S, Guillamo JS, Christov C, et al. Antiangiogenic therapy against experimental glioblastoma using genetically engineered cells producing interferon-alpha, angiostatin, or endostatin. Hum Gene Ther. 2003;14:883-895.
30. de Boüard S, Christov C, Guillamo JS, et al. Invasion of human glioma biopsy specimens in cultures of rodent brain slices: a quantitative analysis. J Neurosurg. 2002;97:169-176.
31. Stoppini L, Buchs PA, Muller D. A simple method for organotypic cultures of nervous tissue. J Neurosci Methods. 1991;37:173-182.
32. Guillamo JS, Lisovoski F, Christov C, et al. Migration pathways of human glioblastoma cells xenografted into the immunosuppressed rat brain. J Neurooncol. 2001;52:205-215.
33. Gommes CJ, de Jong K, Pirard JP, Blacher S. Assessment of the 3D localization of metallic nanoparticles in Pd/Si02 cogelled catalysts by electron tomography. Langmuir. 2005;20:12378-12385.
34. Howard CV, Reed MG. Unbiased Stereology, Three-Dimensional Measurement in Microscopy. Guildford, UK: BIOS Scientific Publishers; 1998.
35. Angers-Loustau A, Hering R, Werbowetski TE, Kaplan DR, Del Maestro RF. SRC regulates actin dynamics and invasion of malignant glial cells in three dimensions. Mol Cancer Res. 2004;2:595-605.
36. Jones G, Machado J Jr, Merlo A. Loss of focal adhesion kinase (FAK) inhibits epidermal growth factor receptor-dependent migration and induces aggregation of nh(2)-terminal FAK in the nuclei of apoptotic glioblastoma cells. Cancer Res. 2001;61:4978-4981.
37. Jones G, Machado J Jr, Tolnay M, Merlo A. PTEN-independent induction of caspase-mediated cell death and reduced invasion by the focal adh esion targeting domain (FAT) in human astrocytic brain tumors which highly express focal adhesion kinase (FAK). Cancer Res. 2001;61:5688-5691.
38. Morimoto AM, Tan N, West K, et al. Gene expression profiling of human colon xenograft tumors following treatment with SU11248, a multitar-geted tyrosine kinase inhibitor. Oncogene. 2004;23:1618-1626.
39. Feltes CM, Kudo A, Blaschuk 0, Byers SW. An alternatively spliced cadherin-11 enhances human breast cancer cell invasion. Cancer Res. 2002;62:6688-6697.
40. Kashima T, Nakamura K, Kawaguchi J, et al. 0verexpression of cadherins suppresses pulmonary metastasis of osteosarcoma in vivo. Int J Cancer. 2003;20:147-154.
41. Motzer RJ, H oosen S, Bello CL, Christensen JG. Sunitinib malate for the treatment of solid tumours: a review of current clinical data. Expert Opin Investig Drugs. 2006;15:553-561.
42. Kunkel P, Ulbricht U, Bohlen P, et al. Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2. Cancer Res. 2001;61:6624-6628.
43. Rubenstein JL, Kim J, 0zawa T, et al. Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption. Neoplasia. 2000;2:306-314.
44. Pennacchietti S, Michieli P, Galluzzo M, Mazzone M, Giordano S, Comoglio PM. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell. 2003;3:347-361.
45. Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with car-boplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol. 2004;22:2184-2191.